Skip to main content
. Author manuscript; available in PMC: 2017 Aug 17.
Published in final edited form as: Mol Cancer Ther. 2015 Jun 10;14(8):1962–1971. doi: 10.1158/1535-7163.MCT-15-0153

Table 2.

Summary of Patients

Patient Melanoma
Type		 Biopsy site Time
from
consent
to biopsy
(days)		 Time
from
biopsy
to
clinical
tumor
board
(days)		 Available target for
clinical treatment
recommendation?
001 Cutaneous Left inguinal lymph node 1 59 Yes
002 Cutaneous Retroperitoneal lymph node 2 37 Yes
003 Cutaneous Left inguinal mass 2 37 Yes
004 Mucosal Liver mass 1 30 Yes
005 Cutaneous Left iliac mass 1 32 Yes